Moral Hazard Dilemma: Worksheet 2 - Beginner Practice Moral Hazard Dilemma BEGINNER

Statement: An insurance company has been denying legitimate claims to boost profits. Whistleblowers have exposed this practice. The company argues that paying all claims would make their products unaffordable for everyone. Course of Action: I. I. The insurance regulator should impose heavy fines and mandate compensation to affected policyholders. II. II. Senior executives responsible for the policy should be prosecuted for fraud. III. III. The company should be allowed to continue its practices as market forces will punish them eventually. IV. IV. Independent audit of all denied claims should be conducted to identify all affected customers. V. V. New regulations should be introduced requiring transparent claims processing and third-party oversight.

Statement: A pharmaceutical company has been selling a life-saving drug at exorbitant prices, making it unaffordable for most patients. The company claims high prices are necessary to recover R&D costs. Course of Action: I. I. The government should invoke compulsory licensing to allow generic production. II. II. The company should be allowed to continue as price controls would discourage future innovation. III. III. Price negotiations should be conducted with the company to find a sustainable pricing model. IV. IV. Government subsidies should be provided to make the drug affordable for low-income patients. V. V. International pressure should be applied to force the company to lower prices globally.

Statement: A pharmaceutical company has been selling a life-saving drug at exorbitant prices, making it unaffordable for most patients. The company claims high prices are necessary to recover R&D costs. Course of Action: I. I. The government should invoke compulsory licensing to allow generic production. II. II. The company should be allowed to continue as price controls would discourage future innovation. III. III. Price negotiations should be conducted with the company to find a sustainable pricing model. IV. IV. Government subsidies should be provided to make the drug affordable for low-income patients. V. V. International pressure should be applied to force the company to lower prices globally.

Statement: An insurance company has been denying legitimate claims to boost profits. Whistleblowers have exposed this practice. The company argues that paying all claims would make their products unaffordable for everyone. Course of Action: I. I. The insurance regulator should impose heavy fines and mandate compensation to affected policyholders. II. II. Senior executives responsible for the policy should be prosecuted for fraud. III. III. The company should be allowed to continue its practices as market forces will punish them eventually. IV. IV. Independent audit of all denied claims should be conducted to identify all affected customers. V. V. New regulations should be introduced requiring transparent claims processing and third-party oversight.

Statement: A systemically important private retirement fund has made excessively risky investments and is now facing imminent collapse. While the failure would cause immediate financial ruin for millions of retirees, a government bailout would incentivize other funds to take similar reckless risks in the future (Moral Hazard). Course of Action: I. I. Government should provide a time-bound, conditional, liquidity injection to stabilize the fund and prevent a systemic panic. II. II. The current executive and investment teams responsible for the risky decisions should be immediately dismissed and face a full regulatory investigation. III. III. The fund should be allowed to fail completely, forcing the market to bear the cost and reinforcing the principle of risk-taking accountability. IV. IV. Regulatory oversight laws governing retirement fund investment limits should be immediately reviewed and significantly tightened. V. V. Affected retirees should be fully compensated using taxpayer money without any requirement for management change or reform.

Statement: A pharmaceutical company has been selling a life-saving drug at exorbitant prices, making it unaffordable for most patients. The company claims high prices are necessary to recover R&D costs. Course of Action: I. I. The government should invoke compulsory licensing to allow generic production. II. II. The company should be allowed to continue as price controls would discourage future innovation. III. III. Price negotiations should be conducted with the company to find a sustainable pricing model. IV. IV. Government subsidies should be provided to make the drug affordable for low-income patients. V. V. International pressure should be applied to force the company to lower prices globally.

Statement: A pharmaceutical company has been selling a life-saving drug at exorbitant prices, making it unaffordable for most patients. The company claims high prices are necessary to recover R&D costs. Course of Action: I. I. The government should invoke compulsory licensing to allow generic production. II. II. The company should be allowed to continue as price controls would discourage future innovation. III. III. Price negotiations should be conducted with the company to find a sustainable pricing model. IV. IV. Government subsidies should be provided to make the drug affordable for low-income patients. V. V. International pressure should be applied to force the company to lower prices globally.

Statement: A systemically important private retirement fund has made excessively risky investments and is now facing imminent collapse. While the failure would cause immediate financial ruin for millions of retirees, a government bailout would incentivize other funds to take similar reckless risks in the future (Moral Hazard). Course of Action: I. I. Government should provide a time-bound, conditional, liquidity injection to stabilize the fund and prevent a systemic panic. II. II. The current executive and investment teams responsible for the risky decisions should be immediately dismissed and face a full regulatory investigation. III. III. The fund should be allowed to fail completely, forcing the market to bear the cost and reinforcing the principle of risk-taking accountability. IV. IV. Regulatory oversight laws governing retirement fund investment limits should be immediately reviewed and significantly tightened. V. V. Affected retirees should be fully compensated using taxpayer money without any requirement for management change or reform.

Statement: An insurance company has been denying legitimate claims to boost profits. Whistleblowers have exposed this practice. The company argues that paying all claims would make their products unaffordable for everyone. Course of Action: I. I. The insurance regulator should impose heavy fines and mandate compensation to affected policyholders. II. II. Senior executives responsible for the policy should be prosecuted for fraud. III. III. The company should be allowed to continue its practices as market forces will punish them eventually. IV. IV. Independent audit of all denied claims should be conducted to identify all affected customers. V. V. New regulations should be introduced requiring transparent claims processing and third-party oversight.

Statement: A pharmaceutical company has been selling a life-saving drug at exorbitant prices, making it unaffordable for most patients. The company claims high prices are necessary to recover R&D costs. Course of Action: I. I. The government should invoke compulsory licensing to allow generic production. II. II. The company should be allowed to continue as price controls would discourage future innovation. III. III. Price negotiations should be conducted with the company to find a sustainable pricing model. IV. IV. Government subsidies should be provided to make the drug affordable for low-income patients. V. V. International pressure should be applied to force the company to lower prices globally.

Statement: An insurance company has been denying legitimate claims to boost profits. Whistleblowers have exposed this practice. The company argues that paying all claims would make their products unaffordable for everyone. Course of Action: I. I. The insurance regulator should impose heavy fines and mandate compensation to affected policyholders. II. II. Senior executives responsible for the policy should be prosecuted for fraud. III. III. The company should be allowed to continue its practices as market forces will punish them eventually. IV. IV. Independent audit of all denied claims should be conducted to identify all affected customers. V. V. New regulations should be introduced requiring transparent claims processing and third-party oversight.

Statement: A systemically important private retirement fund has made excessively risky investments and is now facing imminent collapse. While the failure would cause immediate financial ruin for millions of retirees, a government bailout would incentivize other funds to take similar reckless risks in the future (Moral Hazard). Course of Action: I. I. Government should provide a time-bound, conditional, liquidity injection to stabilize the fund and prevent a systemic panic. II. II. The current executive and investment teams responsible for the risky decisions should be immediately dismissed and face a full regulatory investigation. III. III. The fund should be allowed to fail completely, forcing the market to bear the cost and reinforcing the principle of risk-taking accountability. IV. IV. Regulatory oversight laws governing retirement fund investment limits should be immediately reviewed and significantly tightened. V. V. Affected retirees should be fully compensated using taxpayer money without any requirement for management change or reform.

Statement: A pharmaceutical company has been selling a life-saving drug at exorbitant prices, making it unaffordable for most patients. The company claims high prices are necessary to recover R&D costs. Course of Action: I. I. The government should invoke compulsory licensing to allow generic production. II. II. The company should be allowed to continue as price controls would discourage future innovation. III. III. Price negotiations should be conducted with the company to find a sustainable pricing model. IV. IV. Government subsidies should be provided to make the drug affordable for low-income patients. V. V. International pressure should be applied to force the company to lower prices globally.

Statement: A systemically important private retirement fund has made excessively risky investments and is now facing imminent collapse. While the failure would cause immediate financial ruin for millions of retirees, a government bailout would incentivize other funds to take similar reckless risks in the future (Moral Hazard). Course of Action: I. I. Government should provide a time-bound, conditional, liquidity injection to stabilize the fund and prevent a systemic panic. II. II. The current executive and investment teams responsible for the risky decisions should be immediately dismissed and face a full regulatory investigation. III. III. The fund should be allowed to fail completely, forcing the market to bear the cost and reinforcing the principle of risk-taking accountability. IV. IV. Regulatory oversight laws governing retirement fund investment limits should be immediately reviewed and significantly tightened. V. V. Affected retirees should be fully compensated using taxpayer money without any requirement for management change or reform.

Statement: An insurance company has been denying legitimate claims to boost profits. Whistleblowers have exposed this practice. The company argues that paying all claims would make their products unaffordable for everyone. Course of Action: I. I. The insurance regulator should impose heavy fines and mandate compensation to affected policyholders. II. II. Senior executives responsible for the policy should be prosecuted for fraud. III. III. The company should be allowed to continue its practices as market forces will punish them eventually. IV. IV. Independent audit of all denied claims should be conducted to identify all affected customers. V. V. New regulations should be introduced requiring transparent claims processing and third-party oversight.

Statement: A systemically important private retirement fund has made excessively risky investments and is now facing imminent collapse. While the failure would cause immediate financial ruin for millions of retirees, a government bailout would incentivize other funds to take similar reckless risks in the future (Moral Hazard). Course of Action: I. I. Government should provide a time-bound, conditional, liquidity injection to stabilize the fund and prevent a systemic panic. II. II. The current executive and investment teams responsible for the risky decisions should be immediately dismissed and face a full regulatory investigation. III. III. The fund should be allowed to fail completely, forcing the market to bear the cost and reinforcing the principle of risk-taking accountability. IV. IV. Regulatory oversight laws governing retirement fund investment limits should be immediately reviewed and significantly tightened. V. V. Affected retirees should be fully compensated using taxpayer money without any requirement for management change or reform.

Statement: A systemically important private retirement fund has made excessively risky investments and is now facing imminent collapse. While the failure would cause immediate financial ruin for millions of retirees, a government bailout would incentivize other funds to take similar reckless risks in the future (Moral Hazard). Course of Action: I. I. Government should provide a time-bound, conditional, liquidity injection to stabilize the fund and prevent a systemic panic. II. II. The current executive and investment teams responsible for the risky decisions should be immediately dismissed and face a full regulatory investigation. III. III. The fund should be allowed to fail completely, forcing the market to bear the cost and reinforcing the principle of risk-taking accountability. IV. IV. Regulatory oversight laws governing retirement fund investment limits should be immediately reviewed and significantly tightened. V. V. Affected retirees should be fully compensated using taxpayer money without any requirement for management change or reform.

Statement: A pharmaceutical company has been selling a life-saving drug at exorbitant prices, making it unaffordable for most patients. The company claims high prices are necessary to recover R&D costs. Course of Action: I. I. The government should invoke compulsory licensing to allow generic production. II. II. The company should be allowed to continue as price controls would discourage future innovation. III. III. Price negotiations should be conducted with the company to find a sustainable pricing model. IV. IV. Government subsidies should be provided to make the drug affordable for low-income patients. V. V. International pressure should be applied to force the company to lower prices globally.

Statement: An insurance company has been denying legitimate claims to boost profits. Whistleblowers have exposed this practice. The company argues that paying all claims would make their products unaffordable for everyone. Course of Action: I. I. The insurance regulator should impose heavy fines and mandate compensation to affected policyholders. II. II. Senior executives responsible for the policy should be prosecuted for fraud. III. III. The company should be allowed to continue its practices as market forces will punish them eventually. IV. IV. Independent audit of all denied claims should be conducted to identify all affected customers. V. V. New regulations should be introduced requiring transparent claims processing and third-party oversight.

Statement: A pharmaceutical company has been selling a life-saving drug at exorbitant prices, making it unaffordable for most patients. The company claims high prices are necessary to recover R&D costs. Course of Action: I. I. The government should invoke compulsory licensing to allow generic production. II. II. The company should be allowed to continue as price controls would discourage future innovation. III. III. Price negotiations should be conducted with the company to find a sustainable pricing model. IV. IV. Government subsidies should be provided to make the drug affordable for low-income patients. V. V. International pressure should be applied to force the company to lower prices globally.